The wet AMD market is dominated by three therapies—Roche / Genentech / Novartis’s Lucentis, approved for wet AMD, Roche / Genentech / Chugai’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD, and Regeneron / Bayer HealthCare / Santen’s Eylea, which has experienced strong and continued uptake at the expense of the other VEGF inhibitors. Although the majority of AMD patients are diagnosed with the dry form of AMD, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. While the bulk of emerging therapies target wet AMD patients because the pathology presents clearer drug targets, there are a small number of novel therapies being tested in patients with the dry form of AMD—an indication that has been plagued by several Phase III failures.
- Do KOLs perceive any differences between the mainstays Avastin, Eylea, and Lucentis? How is their use expected to change, if at all, over the next ten years?
- Biosimilar versions of Eylea and Lucentis are forecast to launch within the next five years. What is the likely impact of these therapies on current and emerging VEGF inhibitors?
- A substantial unmet need in wet AMD exists for therapies with longer dosing intervals than offered by current therapies. To what extent are the new and emerging VEGF inhibitors brolucizumab (Beovu; Novartis), abicipar pegol (Allergan), the ranibizumab port delivery system (Roche), and conbercept (Chengdu Kanghong Biotech) as well as the emerging VEGF / Ang-2 inhibitor faricimab (Roche) expected to capitalize on this unmet need?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 18 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: Ten-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III/PR: 7 drugs; Phase II/III: 1 drug; key early-phase therapies.